

[Subscribe](#)

[Past Issues](#)

[Translate](#) ▼

[RSS](#) 

[View this email in your browser](#)



## [ITOG Leadership](#)

### **Executive Committee**

**Manisha H. Shah, MD, Chair**

The Ohio State University

**Sareh Parangi, MD, Secretary**

Harvard Medical School

**David Pfister, MD,**

**Chair, Protocol Committee**

Memorial Sloan-Kettering Cancer Center

**Eric Sherman, MD,**

**Co-Chair Protocol Committee**

Memorial Sloan-Kettering Cancer Center

**Dwight Vicks III MBA Treasurer**

President, Vicks, Inc.

**Lori Wirth, Immediate Past Chairperson**

Massachusetts General Hospital

### **Board of Directors**

**Keith C. Bible, M.D., Ph.D.**

Mayo Clinic (Rochester)

**Naifa Busaidy, MD**

MD Anderson Cancer Center

**Maria Cabanillas, MD**

MD Anderson Cancer Center

**James Fagin, MD**

Memorial Sloan-Kettering

**Andrew Gianoukakis, MD**

University of California, Los Angeles

**Elizabeth Grubbs, MD**

MD Anderson Cancer Center

**Bryan Haugen, MD**

University of Colorado, Health Sciences Center

**Alan Ho MD, PhD**

Memorial Sloan-Kettering

**Gregory Randolph,**

MD Massachusetts Eye and Ear Infirmary

**Bruce G. Robinson,**

MD University of Sydney

**Julie Ann Sosa, M.D.**

University of California, San Francisco

## **ITOG Chair Quarterly Update Newsletter April 2019**

**Manisha Shah, MD**

## ITOG Chair



Dear ITOG Friends!

Happy Spring 2019! Hope that this season brings you lots of positive energy and enthusiasm that feeds your soul and your passion! I look forward to seeing everyone later this week at the 2019 Annual ITOG Meeting in NYC and will miss those who are unable to attend. Many thanks to Drs. David Pfister, Eric Sherman and the rest of the team at MSKCC and Yariv Hourvas from Weill Cornell Medical College for planning excellent meeting with 'one of a kind' agenda for entire meeting that will mainly focus on Thyroid Cancer!.

Since our first quarterly newsletter in Jan 2019, we have several updates at ITOG that I am delighted to share with you as top news items below. I look forward to having a dialogue with you while I share ITOG's progress this past year and new initiatives at the Business Meeting on Saturday, May 4<sup>th</sup> in NYC.

On a personal level, I wanted to give you heads up about my bald head that is in solidarity with my family member diagnosed with Hodgkin's lymphoma in mid-March 2019. I am stronger being able to take cancer journey with her and we are aiming for a cure! Such personal experiences fuel my duty at ITOG to do my best to catalyze cure for thyroid cancer working with all of you! ITOG is so lucky to be able to count on each and every one of us so let's go!

[www.ITOG.org](http://www.ITOG.org)

---

## **ITOG Active Clinical Trials**

[ACCRU/ITOG 1504 Combination Immunotherapy with Multikinase Inhibitor \(MKI\) in Progressive, Radiodine-resistant Differentiated Thyroid Cancers](#)

**Accrual Status:** Accruing

**Accrual Goal:** 60

**Current Accrual:** 46 (Cohort 1 - 30 Cohort 2 - 16)

**Sponsors:** Eisai/Merck

**Coordinating organization:** ACCRU

**Principal Investigator (PI):** Bryan Haugen, MD at University of Colorado Medical Center

Principal Investigator Email: [Bryan.Haugen@ucdenver.edu](mailto:Bryan.Haugen@ucdenver.edu)

**Co-PI:** Lori Wirth, MD

**Publication/Presentation Status:** Pending

**\*\*\*Status Change March 26, 2019 - Cohort 1 is permanently closed to patient accrual per protocol as of March 26, 2019.**

-----  
[Selumetinib plus RAI for RAI-Avid Thyroid Cancers](#)

**Accrual Status:** Accruing

**Accrual Goal:** 60

**Current Accrual:** 51

**Sponsor:** Astrazeneca

**Coordinating organization:** ACCRU

**Principal Investigator:** Alan Ho, MD at Memorial Sloan-Kettering Cancer Center

Principal Investigator Email: [hoa@mskcc.org](mailto:hoa@mskcc.org)

**Co-PI:** Mabel Ryder, MD

**Publication/Presentation Status:** Pending

-----

[Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer \(LIBRETTO-001\)](#)

**Accrual Status:** Accruing

**Sponsor:** Loxo-Oncology

**Coordinating organization:** LOXO-Oncology

**Leader at ITOG:** Lori Wirth and ITOG protocol-specific steering committee

Leader Email: [Lwirth@mgh.harvard.edu](mailto:Lwirth@mgh.harvard.edu)

**Publication Status:** Pending

**Presentations:** ASCO Jun 2018, ATA Oct 2018

-----

[Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy](#)

**Accrual Status:** Permanently closed

**Accrual Goal:** 25

**Current Accrual:** 25

**Sponsors:** CTEP/NCI, ITOG

Coordinating organization: ACCRU

**Principal Investigator:** Manisha Shah, MD at The Ohio State University

Principal Investigator Email: [manisha.shah@osumc.edu](mailto:manisha.shah@osumc.edu)

Co-PI: Maria Cabanillas, MD

**Publication Status:** Published Journal of Clinical Oncology - Oct 2017 [JCO.2017.73.0226](#)

**Presentations:** ASCO Annual Meeting Jun 2017, National Cancer Institute CTEP Cabozantinib Investigators Meeting (2015, 2017), 15<sup>th</sup> International Thyroid Congress (Oct 2015).

-----

[An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer \(ATC\)](#)

**Accrual Status:** Terminated

**Sponsor:** Eisai

**Coordinating organization:** Eisai

**Leader at ITOG:** Lori Wirth and ITOG protocol-specific steering committee

Leader Email: [LWIRTH@mgh.harvard.edu](mailto:LWIRTH@mgh.harvard.edu)

**Publication/Presentation Status:** Pending

-----

[ALLIANCE A091302](#)

Randomized Phase II Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer (PI- Dr. E. Sherman); Alliance study, but with disappointing accrual. Collaboration with ITOG with acknowledgement based on criteria of accrual at ITOG centers. Currently 26 patients accrued; target is 30-34 patients. University of Michigan and Ohio State have already opened the study. Mass General and Fox Chase Cancer Center are about to open.

Target Accrual goal: 30

Accrued to date: 30

**Principal Investigator:** Eric Sherman, MD Memorial-Sloan Kettering Cancer Center

Principal Investigator Email: [shermane@mskcc.org](mailto:shermane@mskcc.org)

## **ITOG Upcoming Trials**

**CTEP approved LOI #10240:** Phase II Study of Cabozantinib in combination with Nivolumab and Ipilimumab (CaboNivolpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after 1 Prior VEGFR-Targeted Therapy

*(Protocol in Development)*

Principal Investigator: Bhavana Konda, MD

Principle Investigator Email: [Bhavana.Konda@osumc.edu](mailto:Bhavana.Konda@osumc.edu)

The Ohio State University

**OSU 17277: A Phase 1 Trial of concurrent Intensity Modulated Radiation Therapy (IMRT) and DABRAFENIB/TRAMETINIB IN BRAF MUTATED ANAPLASTIC OR POORLY DIFFERENTIATED THYROID CANCER**

*(In Development)*

Principal Investigator: Manisah Shah, MD  
Principle Investigator Email: [Manisha.shah@osumc.edu](mailto:Manisha.shah@osumc.edu)  
The Ohio State University

## ITOG TOP NEWS!

**The 2019 ITOG Annual Meeting is around the corner!!**

**Friday May 3 - Sunday May 5, 2019**

**Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center Auditorium**

**417 E. 68th St, New York, NY 10065**

**Many thanks to ITOG members at the MSKCC and Weill Cornell for hosting** this meeting. For any questions, please contact [Afia Sultana](#) or [David Pfister](#) by email, or call 646-888-4237.

**\*\*Registrations as of 4/22/19 - 78**

[Click here to Register](#)

### ***Nearby Accommodations***

**The Helmsley Medical Tower** 1320 York Ave between E.70 and 71<sup>st</sup> St, New York, NY 10021

[The Helmsley Medical Tower Reservations](#) 212-472-8400

**Gardens Suites Hotel by Affinia** 215 E 64th St, New York, NY 10065

[Garden Suites Hotel Reservations](#) (212) 355-1230

**Loews Regency New York** 540 Park Ave, New York, NY 10065

[Loews Regency Reservations](#) (212) 759-4100


**Renaissance New York Hotel** 57130 E 57th St, New York, NY 10022

[Renaissance New York Hotel 57 Reservations](#) (212) 753-8841

---

**Thank you David G. Pfister M.D. and the MSKCC 2019 ITOG Annual Meeting Host Committee Eric Sherman, Alan Ho, Michael Tuttle, Yariv Houvras!**

We are looking forward to the New Agenda Format in which the Protocol Committee Task Force Leaders Committee had greater responsibility for speaker selection and planning the panels.



**Bryan R. Haugen M.D.**, Endocrinology

[University of Colorado Health Sciences Center](#)

Congratulations to Dr. Haugen and participating sites on achieving Accrual Goal of 30 Cohort 1, in ACCRU/ITOG 1504 Clinical Trial.

Participating Sites below

Participating Sites						
*Site Status Key: N=Not Active, A=Active, Not Recruiting, R=Recruiting, C=Closed, D=Dropped						
Sites	Date Site Selected	Regulatory Ready	1st Patient Enrolled	Last Patient Enrolled	Site Status	Site Accrual
1 Dana-Farber Cancer Institute	5/24/2016	3/19/2018	3/30/2018		R	8
2 Los Angeles Biomedical Research	5/24/2016	3/7/2018	6/22/2018		R	3
3 M D Anderson Cancer Center	5/24/2016	3/21/2018	5/14/2018		R	4
4 Memorial Sloan Kettering Cancer Center	5/24/2016	8/17/2018	9/19/2018		R	5
5 Ohio State University Comprehensive	7/16/2018	12/14/2018	1/2/2019		R	6
6 UC San Diego Moores Cancer Center	7/16/2018				N	
7 University of Colorado Hospital	5/24/2016	3/28/2018	5/11/2018		R	10
8 University of Michigan Comprehensive	5/24/2016	4/24/2018	8/22/2018		R	10
9 Vanderbilt University Medical Center	10/31/2018				N	0

**Robert F. Gagel, M.D. Endocrinology**

[MD Anderson Cancer Center](#)

**Lifetime Achievement Award,**

MEN International Workshop

Houston, TX March 27, 2019

*Pictured L-R, Andrew (son), Beth (daughter), Margo (wife), Robert (Bob) Gagel*



**Kenneth D. Burman M.D. Endocrinology**

[Washington Hospital Center](#)

**Outstanding Educator Award**

Endocrine Society, January 2019

Dr. Burman is an extraordinary clinician and teacher who has contributed significantly to the Endocrine Society missions of education and science.

**Matthew Ringel M.D. Endocrinology**

[Ohio State University](#)

Elected to membership in the

**Association of American Physicians (AAP)**

Dr. Ringel was selected based on his seminal discoveries that have significantly contributed to our understanding of the molecular pathogenesis of thyroid cancer.



**ITOG/REACT Merger Update**

The merger of REACT and ITOG was unanimously approved by ITOG members and successfully

completed at the end of December 2018. We are most grateful to Michelle LeBeau's mother Donna, and sister Kimberly Caplea, for choosing ITOG to carry on Michelle's legacy. In Donna's words, "ITOG is the preeminent organization that brings together the leaders in the field to develop better treatments for all types of thyroid cancer, including MTC."

**Donna LeBeau and Kimberly Caplea will be attending the 2019 ITOG Annual Meeting when ITOG members will convey their appreciation for joining forces.**



**There is still time to submit your request!**

**Call for ITOG Committee Members**

**Terms May 2019 – April 2022**

[Click Here to Volunteer for ITOG Committees](#)

- > Basic Science and Correlative Science
- > Clinical Protocols
- > Finance
- > Website and Communications
- > Annual Meeting Planning Task Force
- > By-Laws
- > Development
- > Membership
- > Conflict of Interest

**Call for Hosting 2021 ITOG Annual Meeting**

**Call for 2021 Annual Meeting Host Now Open**

**[Click here to Volunteer to Host the 2021 ITOG Annual Meeting](#)**

**Or email the Chair at [Manisha.shah@osumc.edu](mailto:Manisha.shah@osumc.edu) or [judy.dallas@osumc.edu](mailto:judy.dallas@osumc.edu)**

**Member Feedback**

---

## Thyroid Cancer News

### [Lilly Announces Agreement To Acquire Loxo Oncology](#)

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines through the addition of a marketed therapy and a pipeline of highly selective potential medicines for patients with genomically defined cancers. Loxo Oncology's pipeline includes LOXO-292, an oral RET inhibitor being studied across multiple tumor types, which recently was granted Breakthrough Therapy designation by the FDA and could launch in 2020.

---

## 2019 National and International Meetings And Events

- [ITOG Annual Meeting May 3-5, New York, NY](#)
- [Alliance 2019 Spring Group Meeting May 9 – 11, 2019 Rosemont, IL](#)
- [BIT's 12th Annual World Cancer Congress 2019 May 15-17, Osaka, Japan](#)
- [ASCO 2019 May 21 – June 4, Chicago, IL](#)
- [World Congress on Thyroid Cancer 3.5, June 20 – 22, Rome, Italy](#)

- [NANETS Annual Symposium October 3-5, Boston, MA](#)
- [ThyCa 22nd International Conference October 18 – 20, Denver, CO](#)
- [ATA 89th Annual Meeting October 30-November 3, Chicago, IL](#)
- [Alliance 2019 Fall Group Meeting November 7 – 9, Rosemont, IL](#)
- [42nd Annual Meeting of the European Thyroid Association September 7 – 10 Budapest, Hungary](#)

## Member Feedback

### Development

Donations to ITOG support our mission to catalyze a cure for thyroid cancer. Thyroid cancer has been relatively underfunded compared to other solid tumors. ITOG and its members have played a critical role in organizing the most sophisticated clinical trials to discover and characterize new drugs for thyroid cancer treatment. Your support will make a difference. Philanthropy is a key for ITOG to achieve success. Hundreds of individuals whose lives have been touched by thyroid cancer have contributed to our mission. Make your voice heard by donating today.

ITOG is a 501(c)(3) tax-exempt public charity. Donations are tax deductible.

## Donate Today



## Get Involved

### Submit an Item to the ITOG Monthly Update

All submissions must be relevant to the mission and Purpose of ITOG. Please take time to proof and edit submissions. Requesting Member submissions no later than  
February 28, 2019

Please keep in mind we may not use all submissions, but appreciate you sharing. We reserve the right to edit submissions for content and length. Please send to  
[judy.dallas@osumc.edu](mailto:judy.dallas@osumc.edu)

#### Submission Guidelines:

- No more than 150 words
- Include the name of author, job title, email and institution
- All submissions should be saved in MS Word
- Photos and artwork send as .jpg files.
- Recent publications
- Upcoming & recently completed presentations (within 90 days)
  - Organization, Date, Location, Title
- Open Positions for Employment in Your Division/Department
  - Position title, location, contact information



Copyright © 2019 \*International Thyroid Oncology Group (ITOG)\*, All rights reserved.

Want to change how you receive these emails?  
You can [update your preferences](#) or [unsubscribe from this list](#).

